Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06939283 | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma | active not recruiting | Phase 1 / Phase 2 | 100 | Werewolf Therapeutics, Inc.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04850846 | Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | active not recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 9, 2026 |
| clinicaltrials |
| NCT03513562 | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | active not recruiting | Phase 2 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03749018 | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 30 | David Bond, MDOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03933735 | A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 220 | AbbVieINDUSTRY | 2 | Feb 6, 2026 | clinicaltrials |
| NCT06485219 | A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | active not recruiting | Phase 2 | 50 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05460533 | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05563844 | Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | active not recruiting | Phase 2 | 74 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT00882895 | Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 18 | Washington University School of MedicineOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04067037 | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma | active not recruiting | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04745559 | Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy | active not recruiting | Phase 2 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05583149 | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | active not recruiting | Phase 2 | 28 | Patrick C. Johnson, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03842696 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | active not recruiting | Phase 1 / Phase 2 | 43 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | active not recruiting | Phase 2 | 150 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT02718833 | A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | active not recruiting | Phase 2 | 52 | Massachusetts General HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(RedirecTT-1) | active not recruiting | Phase 1 / Phase 2 | 228 | Janssen Research & Development, LLCINDUSTRY | 7 | Jan 16, 2026 | clinicaltrials |
| NCT05222555 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients(MINDway) | active not recruiting | Phase 1 / Phase 2 | 53 | Incyte CorporationINDUSTRY | 9 | Jan 16, 2026 | clinicaltrials |
| NCT01808599 | Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma | active not recruiting | Phase 2 | 112 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Jan 15, 2026 | clinicaltrials |
| NCT05716087 | A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 2 | 62 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03030261 | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | active not recruiting | Phase 2 | 25 | Washington University School of MedicineOTHER | 2 | Jan 12, 2026 | clinicaltrials |
| NCT01746849 | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04572763 | Copanlisib Plus Venetoclax in R/R DLBCL | active not recruiting | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03674411 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | active not recruiting | Phase 2 | 22 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03961672 | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 15 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05952037 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 114 | BeOne MedicinesINDUSTRY | 9 | Jan 2, 2026 | clinicaltrials |
| NCT04604067 | Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. | active not recruiting | Phase 2 | 260 | Swiss Cancer InstituteOTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT05704049 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma(IZALCO) | active not recruiting | Phase 2 | 118 | SanofiINDUSTRY | 7 | Dec 29, 2025 | clinicaltrials |
| NCT05130827 | Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | active not recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT04009109 | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | active not recruiting | Phase 2 | 79 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05801939 | Cevostamab Following CAR T Cell Therapy for RRMM | active not recruiting | Phase 2 | 30 | University of PennsylvaniaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05410418 | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | active not recruiting | Phase 2 | 34 | Washington University School of MedicineOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT02932280 | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | active not recruiting | Phase 1 / Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03620903 | Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | active not recruiting | Phase 2 | 53 | Christian BuskeOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05065554 | ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | active not recruiting | Phase 2 | 12 | Shayna Sarosiek, MDOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03618537 | Ixazomib Maintenance Study in Patients With AL Amyloidosis | active not recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04963946 | STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia(STAIR) | active not recruiting | Phase 2 | 160 | French Innovative Leukemia OrganisationOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04174196 | A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | active not recruiting | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT02570542 | Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07247383 | Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma | active not recruiting | Phase 2 | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT04060277 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT02253316 | Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | active not recruiting | Phase 2 | 236 | Washington University School of MedicineOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02979522 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 59 | TakedaINDUSTRY | 4 | Nov 10, 2025 | clinicaltrials |
| NCT04148430 | A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy | active not recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT04245839 | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)(TRANSCEND FL) | active not recruiting | Phase 2 | 276 | CelgeneINDUSTRY | 10 | Nov 5, 2025 | clinicaltrials |
| NCT03315026 | Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT02323867 | Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies(AB-CliniMACs) | active not recruiting | Phase 2 | 140 | Children's Hospital of PhiladelphiaOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 10, 2026source: clinicaltrials